Showing 4191-4200 of 9734 results for "".
- RoundTable Healthcare Partners Completes Sale of Revision Skincare and Goodier Cosmetics to Gryphon Investorshttps://practicaldermatology.com/news/roundtable-healthcare-partners-completes-sale-of-revision-skincare-and-goodier-cosmetics-to-gryphon-investors/2461000/RoundTable Healthcare Partners completed the previously announced sale of Revision Skincare and Goodier Cosmetics to Gryphon Investors. Terms of the transaction were not disclosed. Revision Skincare’s portfolio includes Nectifirm, Intellishade, D·E·J
- FDA Clears New Lifting Indications for Sofwavehttps://practicaldermatology.com/news/new-indications-for-sofwave/2460996/Sofwave is now U.S. Food and Drug Administration (FDA)-cleared for lifting the eyebrow and lifting lax submental tissue and neck tissue in people aged 22 or older. In addition, the Sofwave system featuring the Company's proprietary Superb TM (Synchronous Ultrasound Parallel Be
- PsA Treatment Snapshot: Study Highlights Trends in PsA Treatment Since 2018https://practicaldermatology.com/news/psa-treatment-snapshot-study-highlights-trends-in-psa-treatment-since-2018/2460985/There’s been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for psoriatic arthritis (PsA) since 2018, which may reflect their inclusion as potential initial therapy in the American College of Rheumatology/National Pso
- Almirall US Supports The Skin Cancer Foundation’s Mobile Skin Cancer Screening Programhttps://practicaldermatology.com/news/almirall-us-supports-the-skin-cancer-foundations-mobile-skin-cancer-screening-program/2460983/Almirall US is supporting The Skin Cancer Foundation’s mobile skin cancer screening program, Destination Healthy Skin. The Destination Healthy Skin RV travels to cities across the US, where local volunteer dermatologists provide free full-body skin cancer screenings in private exam rooms ab
- Skyrizi Improves PsA Signs and Symptomshttps://practicaldermatology.com/news/skyrizi-improves-psa-signs-and-symptoms/2460981/AbbVie’s risankizumab (SKYRIZI) showed greater improvements in psoriatic arthritis (PsA) signs and symptoms compared to treatment with placebo at week 24 in two Phase 3 clinical trials, according to research slated to be presented American College of Rheumatology (ACR) Convergence 2021.
- Nearly One Third of Lupus Patients Show Low Responses to COVID-19 Vaccineshttps://practicaldermatology.com/news/nearly-one-third-of-lupus-patients-show-low-responses-to-covid-19-vaccines/2460980/Nearly 30 percent of lupus patients with had a low response to the new COVID-19 vaccines, finds research presented at ACR Convergence, the American College of Rheumatology’s annual meeting. Since Phase III clinical trials of COVID-19 vaccines excluded people who take im
- RoC Skincare Marks the First National Retinol Dayhttps://practicaldermatology.com/news/roc-skincare-marks-the-first-national-retinol-day/2460977/Just as Americans set back their clocks this weekend, retinol can help turn back the clock on fine lines and wrinkles. That's the message from RoC® Skincare in honor of the first-ever National Retinol Day on Sunday. National Retinol Day has been registered for annual
- European Medicines Agency Set to Review Incyte’s Ruxolitinib Cream in Vitiligohttps://practicaldermatology.com/news/european-medicines-agency-set-to-review-incytes-ruxolitinib-cream-in-vitiligo/2460970/The European Medicines Agency validated the European Marketing Authorization for Incyte’s ruxolitinib cream as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement. The validation of the Marketing Author
- Vivacare Partnership with Asthma and Allergy Network Provides Professional Digital Patient Education Servicehttps://practicaldermatology.com/news/vivacare-partnership-with-asthma-and-allergy-network-provides-professional-digital-patient-education-service/2460956/Through a new partnership, Vivacare and the Asthma and Allergy Network (AAN) will provide a digital patient education service to Vivacare’s 18,000 professional members, including allergists, dermatologists, pediatricians and primary care providers. Personalized “P
- PsO Improves Among Patients Who Switch to Janssen's Tremfya from Adalimumabhttps://practicaldermatology.com/news/pso-improves-among-patients-who-switch-to-janssens-tremfya-from-adalimumab/2460940/A total of 19 abstracts at the European Academy of Dermatology Venereology 30th Anniversary Congress will present data for Janssen’s Tremfya (guselkumab), including data showing an improvement in PASI response for psoriasis (PsO